The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
The Basic Principles of Chimeric Antigen Receptor Design
Open accessAbstract
Chimeric antigen receptors (CAR) are recombinant receptors that provide both antigen-binding and T-cell–activating functions. A multitude of CARs has been reported over the past decade, targeting an array of cell surface tumor antigens. Their biologic functions have dramatically changed following the introduction of tripartite receptors comprising a costimulatory domain, termed second-generation CARs. These have recently shown clinical benefit in patients treated with CD19-targeted autologous T cells. CARs may be combined with costimulatory ligands, chimeric costimulatory receptors, or cytokines to further enhance T-cell potency, specificity, and safety. CARs represent a new class of drugs with exciting potential for cancer immunotherapy. Significance: CARs are a new class of drugs with great potential for cancer immunotherapy. Upon their expression in T lymphocytes, CARs direct potent, targeted immune responses that have recently shown encouraging clinical outcomes in a subset of patients with B-cell malignancies. This review focuses on the design of CARs, including the requirements for optimal antigen recognition and different modalities to provide costimulatory support to targeted T cells, which include the use of second- and third-generation CARs, costimulatory ligands, chimeric costimulatory receptors, and cytokines. Cancer Discov; 3(4); 388–98. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationA human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
(1997) · PubMed · Cited by 1,541
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Self-citationA Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationSavoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Self-citationIrving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 805
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Self-citationBrentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Self-citationDecade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 625
Li, Y. S., Hayakawa, K., & Hardy, R. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.951 · Cited by 559
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Self-citationTargeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Self-citationTill, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 529
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Self-citationGenetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
Self-citationLethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A. D. M., Pouw, N., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 448
Safe harbours for the integration of new DNA in the human genome
Sadelain, M., Papapetrou, E. P., & Bushman, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3179 · Cited by 441
Self-citationCellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
Romeo, C., & Seed, B. (1991) · Cell · doi:10.1016/0092-8674(91)90327-u · Cited by 396
Identification of the Earliest B Lineage Stage in Mouse Bone Marrow
Li, Y.-S., Wasserman, R., Hayakawa, K., & Hardy, R. R. (1996) · Immunity · doi:10.1016/s1074-7613(00)80268-x · Cited by 376
T‐cell receptor binding affinities and kinetics: impact on T‐cell activity and specificity
Stone, J. D., Chervin, A. S., & Kranz, D. M. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.03015.x · Cited by 367
Krause, A., Guo, H.-F., Latouche, J.-B., Tan, C., Cheung, N.-K. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 365
Self-citationIL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Sequence requirements for induction of cytolysis by the T cell antigenFc receptor ζ chain
Romeo, C., Amiot, M., & Seed, B. (1992) · Cell · doi:10.1016/0092-8674(92)90032-8 · Cited by 324
Urbanska, K., Lanitis, E., Poussin, M., Lynn, R. C., Gavin, B. P., Kelderman, S., Yu, J., Scholler, N., & Powell, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3890 · Cited by 322
T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins.
Letourneur, F., & Klausner, R. D. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.8905 · Cited by 307
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
Self-citationSignals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes.
Brocker, T., & Karjalainen, K. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1653 · Cited by 296
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation
Zhao, Y., Zheng, Z., Cohen, C. J., Gattinoni, L., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.688 · Cited by 283
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu, P., Yang, J. C.-H., Cowherd, R., Treisman, J. S., Shafer, G., Eshhar, Z., & Rosenberg, S. A. (1995) · PubMed · Cited by 273
Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283309 · Cited by 266
Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M., & Morgan, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7739 · Cited by 258
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
Gong, M. C., Latouche, J.-B., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 241
Self-citationPeripheral blood lymphocytes as target cells of retroviral vector- mediated gene transfer
Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorati, G., Traversari, C., & Bordignon, C. (1994) · Blood · doi:10.1182/blood.v83.7.1988.1988 · Cited by 239
Markley, J. C., & Sadelain, M. (2010) · Blood · doi:10.1182/blood-2009-09-241398 · Cited by 228
Self-citationTherapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
von Boehmer, H., & Daniel, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 220
Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
New insights into the T cell synapse from single molecule techniques
Dustin, M. L., & Depoil, D. (2011) · Nature Reviews Immunology · doi:10.1038/nri3066 · Cited by 204
Resistance of mature T cells to oncogene transformation
Newrzela, S., Cornils, K., Li, Z., Baum, C., Brugman, M. H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.-L., Fehse, B., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128751 · Cited by 195
Recchia, A., Bonini, C., Magnani, Z., Urbinati, F., Sartori, D., Muraro, S., Tagliafico, E., Bondanza, A., Stanghellini, M. T. L., Bernardi, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507496103 · Cited by 189
Okamoto, S., Mineno, J., Ikeda, H., Fujiwara, H., Yasukawa, M., Shiku, H., & Kato, I. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1450 · Cited by 186
Gallardo, H. F., Tan, C., Ory, D., & Sadelain, M. (1997) · Blood · doi:10.1182/blood.v90.3.952 · Cited by 170
Self-citationTammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R., & Zhou, X. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.122 · Cited by 165
Quintarelli, C., Vera, J., Savoldo, B., Giordano-Attianese, G., Pule, M., Foster, A., Heslop, H., Rooney, C., Brenner, M., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2007-02-072843 · Cited by 164
Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
Ho, W., Blattman, J. N., Dossett, M. L., Yee, C., & Greenberg, P. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00113-2 · Cited by 157
Rational development of high-affinity T-cell receptor-like antibodies
Stewart-Jones, G., Wadle, A., Hombach, A., Shenderov, E., Held, G., Fischer, E., Kleber, S., Nuber, N., Stenner, F., Bauer, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901425106 · Cited by 128
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
Zakrzewski, J. L., Suh, D. Y., Markley, J. C., Smith, O. M., King, C. G., Goldberg, G. L., Jenq, R. R., Holland, A. M., Grubin, J., Cabrera-Pérez, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1395 · Cited by 124
Self-citationJin, Z., Maiti, S. N., Huls, H. M., Singh, H., Olivares, S., Mátés, L., Izsvák, Z., Ivics, Z., Lee, D. A., Champlin, R. E., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.40 · Cited by 117
Kohn, D. B., Dotti, G., Brentjens, R. J., Savoldo, B., Jensen, M. C., Cooper, L. J. N., June, C. H., Rosenberg, S. A., Sadelain, M., & Heslop, H. E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.1 · Cited by 117
Self-citationBirkholz, K., Hombach, A. A., Krug, C., Reuter, S., Kershaw, M. H., Kämpgen, E., Schuler, G., Abken, H., Schaft, N., & Dörrie, J. (2009) · Gene Therapy · doi:10.1038/gt.2008.189 · Cited by 116
Hsu, C., Jones, S. A., Cohen, C. J., Zheng, Z., Kerstann, K. W., Zhou, J., Robbins, P. F., Peng, P. D., Shen, X., Gomes, T. J., et al. (2007) · Blood · doi:10.1182/blood-2006-06-029173 · Cited by 112
Lee, J., Hayman, E. G., Pegram, H. J., Santos, E. B., Heller, G., Sadelain, M., & Brentjens, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0552 · Cited by 106
Self-citationHow do CARs work? Early insights from recent clinical studies targeting CD19
Davila, M. L., Brentjens, R. J., Wang, X., Rivière, I., & Sadelain, M. (2012) · OncoImmunology · doi:10.4161/onci.22524 · Cited by 102
Self-citationSebestyén, Z., Schooten, E., Sals, T., Zaldívar, I., José, E. S., Alarcón, B., Bobisse, S., Rosato, A., Szöllõsi, J., Gratama, J. W., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7736 · Cited by 82
Hülsmeyer, M., Chames, P., Hillig, R. C., Stanfield, R. L., Held, G., Coulie, P. G., Alings, C., Wille, G., Saenger, W., Uchańska‐Ziegler, B., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411323200 · Cited by 76
Kustikova, O. S., Schiedlmeier, B., Brugman, M. H., Stahlhut, M., Bartels, S., Li, Z., & Baum, C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.134 · Cited by 73
Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation
Stanghellini, M. T. L., Provasi, E., Bondanza, A., Ciceri, F., Bordignon, C., & Bonini, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.014 · Cited by 64
Hematopoietic stem cell engineering at a crossroads
Rivière, I., Dunbar, C. E., & Sadelain, M. (2012) · Blood · doi:10.1182/blood-2011-09-349993 · Cited by 54
Self-citationTowards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
Zhou, G., & Levitsky, H. I. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/124187 · Cited by 53
Genetic modification of lymphocytes by retrovirus-based vectors
Suerth, J. D., Schambach, A., & Baum, C. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.007 · Cited by 38
Denkberg, G., & Reiter, Y. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.07.004 · Cited by 36
T cell recognition of weak ligands: roles of signaling, receptor number, and affinity
Edwards, L. J., & Evavold, B. D. (2011) · Immunologic Research · doi:10.1007/s12026-011-8204-3 · Cited by 36
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma
Seaman, B. J., Guardiani, E. A., Brewer, C. C., Zalewski, C. K., King, K. A., Rudy, S., Waes, C. V., Morgan, R. A., Dudley, M. E., Yang, J. C.-H., et al. (2012) · Otolaryngology · doi:10.1177/0194599812448356 · Cited by 36
Kaka, A. S., Shaffer, D. R., Hartmeier, R., Leen, A. M., Lu, A., Bear, A. S., Rooney, C. M., & Foster, A. E. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad4071 · Cited by 34
Chmielewski, M. M., Rappl, G., Hombach, A. A., & Abken, H. (2012) · Gene Therapy · doi:10.1038/gt.2012.21 · Cited by 26
Double or nothing on cancer immunotherapy
Hanada, K., & Restifo, N. P. (2013) · Nature Biotechnology · doi:10.1038/nbt.2471 · Cited by 17
Cooper, L. J. N., Jena, B., & Bollard, C. M. (2012) · Blood · doi:10.1182/blood-2011-12-398719 · Cited by 15
Sadelain, M. (2011) · New England Journal of Medicine · doi:10.1056/nejme1109971 · Cited by 12
Self-citation
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
“One strategy to ameliorate these limitations is through the utilization of delivery routes other than systemic delivery as local administration (1) eliminates the need for CAR-T cells to traffic to disease sites and (2) limits on-target off-tumor toxicities as the CAR-T cells’ on-target activity is directed on tumor c…”
BackgroundAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Metadata
- Authors
- Sadelain, M., Brentjens, R., & Rivière, I.
- Venue
- Cancer Discovery
- Published
- 2013-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 388-398
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2124513722
- Cited by
- 1,535
- References
- 92
- FWCI
- 32.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.